Benzinga | Oct 22, 2020 05:40AM EDT

Kezar Life Sciences on Wednesday Received FDA Orphan Drug Designation for their Treatment for Polymyositis on October 21

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=663518